Field note · August 2026 · Class 003 Manufacturing

MoCRA and the Clean-Room Premium: Why Outsiders Misprice Factory Minimums

The Modernization of Cosmetics Regulation Act (MoCRA), signed in December 2022 and taking full enforcement effect through 2024–2026, fundamentally restructured who can manufacture cosmetics in the United States. Every facility producing cosmetics for US distribution must now register with the FDA, maintain adverse event records, and comply with current Good Manufacturing Practice (cGMP) requirements.

For indie beauty founders, the practical consequence is simple: the universe of available contract manufacturers just shrank. Facilities that once offered low-MOQ runs for emerging brands are now either upgrading their clean-room infrastructure to meet cGMP standards — or exiting the market.

“MoCRA didn’t create the clean-room premium. It exposed how many manufacturers were operating without one.”

The founders who misprice factory minimums are the ones comparing pre-MoCRA quotes to post-MoCRA reality. A facility that quoted $8,000 for a 2,500-unit batch in 2022 may now quote $14,000–$18,000 for the same run, reflecting real investments in environmental controls, batch documentation, and adverse event reporting infrastructure.

The operators who understand this shift are sourcing capacity from the 1,455 FDA-registered cGMP facilities currently in the domestic network — and locking production windows before Q4 demand cycles absorb remaining availability.

— Vishal Nanda, unovaProcess